Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer

Matsuda, Naoko; Wang, Xiaoping; Lim, Bora; Krishnamurthy, Savitri; Álvarez, Ricardo H.; Willey, Jie; Parker, Charla A.; Song, Juhee; Shen, Yu; Hu, Jianhua; Wu, Wenhui; Li, Nan; Babiera, Gildy; Murray, James L.; Arun, Banu K.; Brewster, Abenaa M.; Reuben, James M.; Stauder, Michael C.; Barnett, Chad M.; Woodward, Wendy A.; Le-Petross, Huong T.; Lucci, Anthony; DeSnyder, Sarah M.; Tripathy, Debu; Valero, Vicente; Ueno, Naoto T.

doi:10.1001/jamaoncol.2018.1436

Cited by 64 publications

(57 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may be correlated with the different pCR rates between these groups. 34,35 In other words, HR-/HER2+ and triple negative tumors had higher PPVs with higher pCR rates, whereas HR +/HER2-tumors had higher NPV and accuracy with a lower pCR rate. Also, maximum primary tumor size before NAC also had a significant impact on the diagnostic performance of US and MRI.…”

Section: Discussionmentioning

confidence: 99%

<p>Prediction of Pathologic Complete Response by Ultrasonography and Magnetic Resonance Imaging After Neoadjuvant Chemotherapy in Patients with Breast Cancer</p>

Zhang¹,

Li²,

Zhu³

et al. 2020

CMAR

View full text Add to dashboard Cite

These authors contributed equally to this workPurpose: To compare the diagnostic performance for pathologic complete response (pCR) in breast cancer after neoadjuvant chemotherapy (NAC) between ultrasound (US) and magnetic resonance imaging (MRI). Patients and Methods: A total of 1,219 breast cancer patients with 1,232 tumors who accepted US and/or MRI examination after NAC and before breast surgery were included. The diagnostic performance of US, MRI, and US plus MRI in predicting pCR was compared. Results: The sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) of US for pCR were 36.2%, 90.2%, 71.0%, 67.3%, and 71.9%, respectively, while for MRI they were 44.4%, 92.9%, 75.6%, 77.7%, and 75.0%, respectively. The combination of US and MRI had increased specificity (98.0%) and PPV (86.8%), decreased sensitivity (22.5%) and NPV (68.8%), but similar accuracy (70.5%) in comparison with US or MRI alone. The prediction of pCR by imaging differed in different histological, molecular subtypes and primary tumor size. Conclusion: Neither US nor MRI could predict a pCR with sufficient accuracy. The combination of US and MRI could not predict a pCR reliably either. The explanation of imaging for pCR should take into account histological, molecular subtypes, and primary tumor size.

show abstract

Section: Discussionmentioning

confidence: 99%

<p>Prediction of Pathologic Complete Response by Ultrasonography and Magnetic Resonance Imaging After Neoadjuvant Chemotherapy in Patients with Breast Cancer</p>

Zhang¹,

Li²,

Zhu³

et al. 2020

CMAR

View full text Add to dashboard Cite

show abstract

“…[31][32][33][34][35] One of DCN's key interacting partners is EGFR, a known mediator of tumorigenesis and metastasis in IBC mouse models and an important therapeutic target in IBC patients. [36][37][38] EGFR is an independent predictor of poor prognosis and increased recurrence in IBC patients, and a promoter of invasion and metastasis in preclinical mouse models. 36,37 Importantly, in a phase II clinical trial, a humanized anti-EGFR antibody panitumumab in combination with neoadjuvant chemotherapy led to remarkably high pathological complete response rate in patients with triple-negative IBC, 38 indicating that EGFR is a promising therapeutic target in IBC.…”

Section: Mainmentioning

confidence: 99%

Decorin, a novel negative modulator of E-cadherin in inflammatory breast cancer

Villodre

Larson

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

ABSTRACTInflammatory breast cancer (IBC) is a clinically distinct and highly aggressive form of breast cancer with rapid onset and a strong propensity to metastasize. The molecular mechanisms underlying the aggressiveness and metastatic propensity of IBC are largely unknown. Herein, we report that decorin (DCN), a small leucine-rich extracellular matrix proteoglycan, is downregulated in tumors from patients with IBC. Overexpression of DCN in IBC cells markedly decreased migration, invasion, and cancer stem cells in vitro and inhibited IBC tumor growth and metastasis in vivo. Mechanistically, DCN functioned as a suppressor of invasion and tumor growth in IBC by destabilizing E-cadherin and inhibiting EGFR/ERK signaling. DCN physically binds E-cadherin in IBC cells and accelerates its degradation through an autophagy-linked lysosomal pathway. We established that DCN inhibits tumorigenesis and metastasis in IBC cells by negatively regulating the E-cadherin/EGFR/ERK axis. Our findings offer a potential therapeutic strategy for IBC, and provide a novel mechanism for IBC pathobiology.

show abstract

“…e absorbance was determined by an ELISA plate reader at a wavelength of 450 nm (FLUOstar Omega, Germany). Finally, the collected data were keyed into to the HN-nonLin software (http://malaria.farch.net) to obtain the 50% effective concentration (EC 50 ) values directly from the graphs. All tests were performed in triplicates.…”

Section: P Falciparum Histidine-rich Protein 2 (Hrp2) Assaymentioning

confidence: 99%

“…Sulforhodamine B (SRB) assay was carried out as described in the previous studies to determine the 50% growth inhibition (GI 50 ) values of all the compounds [32]. Initially, the cells were seeded in 96-well plates at a density of either 1 × 10 5 cells/ml (MCF-7) or 2 × 10 5 cells/ml (MDA-MB-231 and HT-29), after which incubation was done overnight to allow the cells to adhere to the bottom of the plates.…”

Section: In Vitro Cytotoxicity Assaymentioning

confidence: 99%

“…According to the National Cancer Registry 2007 of Malaysia, breast and colorectal cancer also are the most common cancer in Malaysia [48]. One of the main treatments for cancer is chemotherapy [49,50]; however, the development of drug resistance [51,52] and drug toxicity [53] results in significant relapse as well as decreased overall survival rates in cancer patients [54]. us, searching for potential drug with high efficacy and low drug toxicity remains a huge challenge in the anticancer drug discovery research and development.…”

Section: Antiplasmodial Activitymentioning

confidence: 99%

See 1 more Smart Citation

New Silver Complexes with Mixed Thiazolidine and Phosphine Ligands as Highly Potent Antimalarial and Anticancer Agents

Sofyan

Nordin

Razak

et al. 2018

Journal of Chemistry

View full text Add to dashboard Cite

Five silver(I) complexes containing a mixed ligand system of phosphine and thiazolidine were successfully synthesized. e structural information of the complexes was assembled using various spectroscopic techniques such as CHN elemental analysis, Fourier transformed infrared (FTIR), 1 H, 13 C, and 31 P{ 1 H} NMR spectroscopy, and thermogravimetric analysis (TGA). A bidentate phosphine ligand acted as a chelating agent which bond to the silver in 1 : 2 molar ratios. Meanwhile, thiazolidine was attached to the silver in a 1 : 1 molar ratio. e antiplasmodial properties of all synthesized complexes were investigated on chloroquine-resistant P. falciparum parasite via HRP2 assays and cytotoxicity tests on Vero cells. Of all the synthesized complexes, complex 2 showed the highest SI value (more than 12.4) followed by complex 5 (6.6). e potent properties of compounds 2 and 5 were also noted in the in vitro antiproliferative assays involving MDA-MB-231 and MCF-7 breast cancer cell lines as well as HT-29 colon cancer cell line. Complex 2 was selective for MDA-MB-231 cells (GI 50 � 1.9 ± 0.3 µM), while complex 5 acted predominantly on breast carcinoma cells (GI 50 MDA-MB-231 � 4.7 ± 1.1 µM; MCF-7 � 2.9 ± 0.9 µM) instead of colon carcinoma (HT-29) cells (GI 50 � 15.1 ± 1.9 µM).

show abstract

Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer

Abstract: ClinicalTrials.gov Identifier: NCT01036087.

Cited by 64 publications

References 34 publications

<p>Prediction of Pathologic Complete Response by Ultrasonography and Magnetic Resonance Imaging After Neoadjuvant Chemotherapy in Patients with Breast Cancer</p>

<p>Prediction of Pathologic Complete Response by Ultrasonography and Magnetic Resonance Imaging After Neoadjuvant Chemotherapy in Patients with Breast Cancer</p>

Decorin, a novel negative modulator of E-cadherin in inflammatory breast cancer

New Silver Complexes with Mixed Thiazolidine and Phosphine Ligands as Highly Potent Antimalarial and Anticancer Agents

Contact Info

Product

Resources

About